Granted Patent
B2
US 12,583,884 · App. 17/414,826 · Granted Mar 24, 2026
3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders
Inventors:
Pier Vincenzo Piazza (Bordeaux, FR); Sandy Fabre (Bordeaux, FR); Stéphanie Monlezun (Bordeaux, FR); Mathilde Metna (Bordeaux, FR); Monique Vallee (Bordeaux, FR); Jean-Michel Revest (Bordeaux, FR); Daniela Cota (Bordeaux, FR); Giovanni Marsicano (Bordeaux, FR); Aline Marighetto (Bordeaux, FR); Andrés Ozaita (Barcelona, ES); Rafael Maldonado (Barcelona, ES)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention generally relates to a specific pregnenolone derivative for its use for the treatment of a cognitive disorders. More particularly, the invention relates to a compound of Formula (I) for its use in the treatment of cognitive disorders. Indeed, the compound of the invention is in vivo very potent in correcting the cognitive impairments observed in cognitive disorders.
Claims (13)
1 . A method of treating a cognitive disorder, comprising administering to a human subject with Down syndrome or Fragile X syndrome and in need thereof a therapeutically effective amount of a compound according to Formula (I):
wherein the compound is administered to the subject at a dose of between 20 μg to 2 mg per day.
2 . The method of claim 1 , wherein the compound according to Formula (I) is administered to the subject by an oral route.
3 . The method of claim 1 , wherein the compound according to Formula (I) is administered to the subject by a parenteral route.
4 . The method of claim 1 , wherein the compound according to Formula (I) is administered to the subject by a route selected from the group consisting of an intravenous route, a subcutaneous route, an intranasal route, and an intramuscular route.
5 . The method of claim 1 , wherein the compound according to Formula (I) is administered to the subject at a dose of between 20 μg to 600 μg per day.
6 . The method of claim 1 , wherein the compound according to Formula (I) is administered to the subject at a dose of 100 μg per day.
7 . The method of claim 1 , wherein the compound according to Formula (I) is administered to the subject at a dose of 200 μg per day.
8 . The method of claim 1 , wherein the compound according to Formula (I) is administered to the subject at a dose of 600 μg per day.
9 . The method of claim 5 , wherein the compound according to Formula (I) is administered to the subject by an oral route.
10 . The method of claim 6 , wherein the compound according to Formula (I) is administered to the subject by an oral route.
11 . The method of claim 7 , wherein the compound according to Formula (I) is administered to the subject by an oral route.
12 . The method of claim 8 , wherein the compound according to Formula (I) is administered to the subject by an oral route.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 10, 2022
From: PIAZZA, PIER VINCENZO; FABRE, SANDY; MONLEZUN, STEPHANIE; METNA, MATHILDE; VALLEE, MONIQUE; REVEST, JEAN-MICHEL; COTA, DANIELA; MARSICANO, GIOVANNI; MARIGHETTO, ALINE; OZAITA, ANDRES; MALDONADO, RAFAEL
To: AELIS FARMA; UNIVERSITE DE BORDEAUX; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Reel/Frame 058596/0559 →
Priority Claims (1)
EP 18306716
· Dec 18, 2018
· regional
Continuity (1)
References Cited (72)
US 20220153776A1
· Piazza et al.
· 2022
[cited by applicant]
CN 101506172A
· 2009
[cited by applicant]
CN 105189529A
· 2015
[cited by applicant]
WO 2008010073A1
· 2008
[cited by applicant]
WO 2012160006A1
· 2012
[cited by applicant]
WO 2014083068A1
· 2014
[cited by applicant]
Annus et al, The Down syndrome brain in the presence and absence of fibrillar Î
[cited by examiner]
Boat et al. (ed), âClinical Characteristics of Intellectual Disabilitiesâ, Ch. 9 of Mental Disorders and Disabilities Among Low-Income Children, National Academies Press (US) (p. 173 only) (Year: 2015).
[cited by examiner]
Glatt et al., âls Schizophrenia A Neurodevelopmental Disorder?â, Ch. 9 of Schizophrenia, Oxford (Abstract only) (Year: 2019).
[cited by examiner]
Morris-Rosendahl et al., Neurodevelopmental disordersathe history and future of a diagnostic concept, Dialog. Clin. Neurosci., 22, pp. 65-72 (Year: 2020).
[cited by examiner]
Murray et al., Is schizophrenia a neurodevelopmental disorder?, Brit. Med. J., 295, p. 681-682 (Year: 1987).
[cited by examiner]
Spitzer et al., Medical and mental disorder: Proposed definition and criteria, Ann. Med. Psychol., rev. psychiatr. (Paris), 176, pp. 656-665 (Year: 2018).
[cited by examiner]
Tsuang, Schizophrenia: genes and environment, Biol. Psych., 47, pp. 210-220 (Year: 2000).
[cited by examiner]
Nair, A simple practice guide for dose conversion between animals and human, J. Basic. Clin. Pharm., 7, pp. 27-31 (Year: 2016).
[cited by examiner]
Marx, C. E. et al, “Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia” Neuropsychopharmacology (2009) 34(8):1885-1903.
[cited by applicant]
International Search Report and Written Opinion for PCT/EP2019/085927, mailed on Mar. 18, 2020.
[cited by applicant]
Breton, M.C. et al., “Traitement pharmacologique de la maladie d'Alzheimer et des maladies apparentées: rapport d'évaluation des technologies de la santé”; (2015); Institut national d'excellence en santé et en services …
[cited by applicant]
“Rapport d'évaluation des médicaments indiqués dans le traitement symptomatique de la maladie d'Alzheimer” (2016); Commission de la Transparence. Haute Autorité de Santé.
[cited by applicant]
Beyer, C.E. et al. “Depression-like phenotype following chronic CB1 receptor antagonism”, (2010), Neurobiology of Disease 39, 148-155.
[cited by applicant]
Hunter J. et al., “Epidemiology of Fragile X Syndrome: A Systematic Review and Meta-Analysis”, (2014), American Journal Medical Genetics 164A, 1648-1658.
[cited by applicant]
Kishnani, P.S. et al., “Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17”, (2010), Journal Medical Genetics A, 152A, 3028-3035.
[cited by applicant]
Kumin L. et al.; Employment in Adults with Down Syndrome in the United States: Results from a National Survey, (2016), Journal of Applied Research in Intellectual Disabilities 29, 330-345.
[cited by applicant]
Marighetto, A. et al., “Studying the impact of aging on memory systems: contribution of two behavioral models in the mouse”, (2012), Current Topics in Behavioral Neuroscience10, 67-89.
[cited by applicant]
Moreira, F.A. et al., “Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression”, (2009), Best Practice & Research Clinical Endocrinology & Metabolism…
[cited by applicant]
Overstreet, D.H., “Modeling Depression in Animal Models”, (2021), Methods in Molecular Biology, 829, 125-144.
[cited by applicant]
Rinaldi-Carmona, M. et al., “Characterization of Two Cloned Human CB1 Cannabinoid Receptor Isoforms”, (1996), Journal Pharmacology Experimental Therapeutics, 278, 871-878.
[cited by applicant]
Varni, J.W. et al., “PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations”, (2001), Medical Care 39, 800-812.
[cited by applicant]
Zavatti, M. et al., “Effects of the cannabinoid antagonist SR 141716 on sexual and motor behaviour in receptive female rats”, (2011), Clinical and Experimental Pharmacology and Physiology, 38, 771-775.
[cited by applicant]
“Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease”, (2011), Technology appraisal guidance, 76 pages.
[cited by applicant]
Kharkevich, D.A., Pharmacology, 10th ed. M.: GEOTAR-Media, 2010, p. 73-74.
[cited by applicant]
Zakharov, V.V., et al. “Cognitive disorders in the elderly and senile age”, a manual for doctors, Moscow, 2005, p. 9, 17, 60.
[cited by applicant]
Zhulenko V.N., et al., G.I. Pharmacology. M.: KolosS, 2008, pp. 34-35.
[cited by applicant]
“Diagnostic and statistical manual of mental disorders”, DSM-5 (2013), Washington, D.C: American Psychiatric Association). pp. xiii-xxxii, 31-86, 591-643, and 839-896.
[cited by applicant]
Goepp, J. “Enhancing Cognitive Function with Pregnenolone”, Life Extension Magazine Nov. 2007, retrieved from the internet at https://www.lifeextension.com/magazine/2007/11/report_pregnenolone (accessed Apr. 19, 2024, a…
[cited by applicant]
Vallee, M. et al, “Neurosteroids and potential therapeutics: focus on pregnenolone”, J. Steroid. Biochem. Mol. Biol. (2015) vol. 160, p. 78-87.
[cited by applicant]
Arnone, M., et al. , “Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors”, (1997), Psychopharmacology (Berl.) 132, 104-106.
[cited by applicant]
Bellocchio, L., et al. , “Activation of the sympathetic nervous system mediates hypophagic and anxiety-like effects of CB, receptor blockade”, (2013), Proc. Natl. Acad. Sci. U.S.A. 110, 4786-4791.
[cited by applicant]
Beringer, P. ,“Remington: the science and practice of pharmacy”, (2011), (Philadelphia; London: Lippincott Williams & Wilkins).
[cited by applicant]
Berry-Kravis, E., et al. “Outcome Measures for Clinical Trials in Fragile X Syndrome”, (2013) Journal of Developmental & Behavioral Pediatrics 34, 508-522.
[cited by applicant]
Burckhardt, C.S., et al. “The Quality of Life Scale (QOLS): reliability, validity, and utilization”, (2003) Health Qual Life Outcomes 1, 60.
[cited by applicant]
Busquets-Garcia, A., et al. “Targeting the endocannabinoid system in the treatment of fragile X syndrome”, (2013), Nature Medicine 19, 603-607.
[cited by applicant]
Carai, M.A.M., et al. “Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data”, (2006), CNS Drug Rev 12, 91-99.
[cited by applicant]
Chang, K.T., et al. “Meeting at the crossroads: common mechanisms in Fragile X and Down syndrome”, (2013), Trends Neurosci. 36, 685-694.
[cited by applicant]
Edgin, J.O., et al. “Human and mouse model cognitive phenotypes in Down syndrome: implications for assessment”, (2012), Prog. Brain Res. 197, 123-151.
[cited by applicant]
Ennaceur, A. “One-trial object recognition in rats and mice: methodological and theoretical issues”, (2010), Behav. Brain Res. 215, 244-254.
[cited by applicant]
Esbensen, A.J., et al. “Outcome Measures for Clinical Trials in Down Syndrome. American Journal on Intellectual and Developmental Disabilities”, (2017), 122, 247-281.
[cited by applicant]
Etchamendy, N., et al. “Evidence for a virtual human analog of a rodent relational memory task: A study of aging and MRI in young adults”, (2012), Hippocampus 22, 869-880.
[cited by applicant]
Gardiner, K.J. “Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations”, (2015), Drug Des Devel Ther 9, 103-125.
[cited by applicant]
Grieco, J., et al. , “Down syndrome: Cognitive and behavioral functioning across the lifespan”, (2015), American Journal of Medical Genetics Part C: Seminars in Medical Genetics 169, 135-149.
[cited by applicant]
Hanney, M., et al. “Memantine for dementia in adults older than 40 years with Down's syndrome (Meadows): a randomised, double-blind, placebo-controlled trial”, (2012), The Lancet 379, 528-536.
[cited by applicant]
Hessl, D., et al. “The NIH Toolbox Cognitive Battery for intellectual disabilities: three preliminary studies and future directions”, (2016), Journal of Neurodevelopmental Disorders 8.
[cited by applicant]
Kazdoba, T.M., et al. “Modeling fragile X syndrome in the Fmr1 knockout mouse” (2014), Intractable Rare Dis Res 3, 118-133.
[cited by applicant]
Laprairie, R.B., et al. “Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons”, (2014) J. Biol. Chem. 289, 24845-24862.
[cited by applicant]
Patel, S., et al. “Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling”, (2006). J. Pharmacol. Exp. Ther. …
[cited by applicant]
Seely, K.A., et al, “AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: Implications for opioid/cannabinoid interaction studies” (2012), Neuropharmacology 63, 905-915.
[cited by applicant]
Bellami, A., et al., “Temporal binding function of dorsal CA1 is critical for declarative memory formation”, (2017), Proc. Natl. Acad. Sci. U.S.A. 114, 10262-10267.
[cited by applicant]
Sheehan, B. “Assessment scales in dementia”, (2012) Ther Adv Neurol Disord 5, 349-358.
[cited by applicant]
Shore, D.M., et al. “Allosteric Modulation of a Cannabinoid G Protein-coupled Receptor: Binding Site Elucidation and Relationship to G Protein Signaling”, (2014), Journal of Biological Chemistry 289, 5828-5845.
[cited by applicant]
Vallee, M., et al. , “Pregnenolone can protect the brain from cannabis intoxication”, (2014), Science 343, 94-98.
[cited by applicant]
Walf, A.A., et al. “The use of the elevated plus maze as an assay of anxiety-related behavior in rodents” (2007), Nat Protoc 2, 322-328.
[cited by applicant]
“Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease” (2011), Technology appraisal guidance. National Institute for Health and Care Excellence.
[cited by applicant]
EPAR discussion. https://www.ema.europa.eu/documents/scientific-discussion/acomplia-epar-scientific-discussion_en.pdf, (2006).
[cited by applicant]